



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/719,695
Filing Date	November 21, 2003
First Named Inventor	Leong Ng
Art Unit	1644
Examiner Name	Not yet known
Attorney Docket Number	ISA-012.01

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Nora Rooney/	Date Considered	10/26/2006
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP §01.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/719,695
		Filing Date	November 21, 2003
		First Named Inventor	Leong Ng
		Art Unit	
		Examiner Name	Not yet known
Sheet 2 of 3	Attorney Docket Number	ISA-012.01	


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NR	AD	Ames et al., "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14," Nature, 401: 282-286 (1999)	
NR	AE	Brenner et al., "Diverse Biological Actions of Atrial Natriuretic Peptide," Physiol. Rev., 70(3): 665-699 (1990)	
NR	AF	Davies et al., "Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study," Lancet, 358: 439-444 (2001)	
NR	AG	Hall, "The value of natriuretic peptides for the management of heart failure: current state of play," Eur J Heart Fail, 3:395-397 (2001)	
NR	AH	Hobbs et al., Br Med J 2002; 324: 1498-1502	
NR	AI	Ikeda et al., "Cloning and expression of cDNA encoding the human 150 kDa oxygen-regulated protein, ORP150," Biochem Biophys Res Commun, 230(1): 94-9 (1997)	
NR	AJ	Karl et al., "Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit," Scand J Clin Lab Invest Suppl, 230:177-181 (1999)	
NR	AK	Kollar et al., "Selective Activation of the B Natriuretic Peptide Receptor by C-Type Natriuretic Peptide (CNP)," Science, 252:120-123 (1991)	
NR	AL	Kuwabara et al., "Purification and Characterization of a Novel Stress Protein, the 150-kDa Oxygen-regulated Protein (ORP150), from Cultured Rat Astrocytes and Its Expression in Ischemic Mouse Brain," J Biol Chem, 271(9): 5025-5032 (1996)	
NR	AM	McDonagh et al., "Biochemical detection of left-ventricular systolic dysfunction," Lancet, 351:9-13 (1998)	
NR	AN	McDonagh et al., "Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population," Lancet, 350: 829-833 (1997)	

Examiner Signature	/Nora Rooney/	Date Considered	10/26/2006
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/719,695		
		Filing Date	November 21, 2003		
		First Named Inventor	Leong Ng		
		Art Unit			
		Examiner Name	Not yet known		
Sheet	3	of	3	Attorney Docket Number	ISA-012.01

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NR	AO	Ng et al, Clinical Science 2002; 102: 411-418	
NR	AP	Stingo et al., "Cardiovascular and renal actions of C-type natriuretic peptide," Am. J. Physiol., 262:H308-H312 (1992)	
NR	AQ	Stingo et al., "Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma," Am. J. Physiol., 263:H1318-H1321 (1992)	
NR	AR	Suga et al., "Endothelial Production of C-Type Natriuretic Peptide and Its Marked Augmentation by Transforming Growth Factor- β ," J. Clin. Invest., 90:1145-1149 (1992)	
NR	AS	Sumar et al., "Lectins as Indicators of Disease-Associated Glycoforms," In: Gabius HDJ & Gabius S (eds.), 1993, Lectins and Glycobiology, at pp. 158-174	

Examiner Signature	/Nora Rooney/	Date Considered	10/26/2006
-----------------------	---------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
 (Use several sheets if necessary)

Docket Number (Optional)

ISA-012.01

Application Number

10/719,695

Applicant

Leong Ng

Filing Date

November 21, 2003

Group Art Unit

Not yet known

1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NR	AT 6,461,828	10/8/02	Stanton et al.			
NR	AU 2002/0103353	08/1/02	Einat et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
NR	AV WO 03/01652	02/27/03	PCT				
NR	AW EP 0 780 472	06/25/97	Europe				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

NR	AX	Ikematsu et al., "The expression of a novel stress protein '150-kDa oxygen regulated protein' in sudden infant death," Legal Medicine 5:15-19 (2003)					
NR	AY	Kobayashi et al., "The Increment of Anti-ORP150 Autoantibody in Initial Stages of Atheroma in High-Fat Diet Fed Mice," Journal of Veterinary Medical Science, 64(2):177-180 (2002)					
NR	AZ	Tsukamoto et al., "150-kD Oxygen-regulated Protein is Expressed in Human Atherosclerotic Plaques and Allows Mononuclear Phagocytes to Withstand Cellular Stress on Exposure to Hypoxia and Modified Low Density Lipoprotein," Journal of Clinical Investigation, 98(8):1930-1941 (1996)					
NR	BA	Copy of International Search Report for PCT/GB 03/05113					

EXAMINER	/Nora Rooney/	DATE CONSIDERED
		10/26/2006

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.